A neuroprotective compound
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

PTIQ

Item No. 33540

Technical Information
Formal Name
1-(3,4-dihydro-7-hydroxy-6-methoxy-2(1H)-isoquinolinyl)-1-propanone
CAS Number
1032822-42-6
Molecular Formula
C13H17NO3
Formula Weight
Purity
≥95%
A solid
DMSO: slightly solubleMethanol: slightly soluble
SMILES
O=C(CC)N1CC2=CC(O)=C(C=C2CC1)OC
InChi Code
InChI=1S/C13H17NO3/c1-3-13(16)14-5-4-9-7-12(17-2)11(15)6-10(9)8-14/h6-7,15H,3-5,8H2,1-2H3
InChi Key
BEDYMEDICHGLSE-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    PTIQ is a neuroprotective compound.1 It inhibits tetrahydro-L-biopterin-induced cytotoxicity and increases in matrix metalloproteinase-3 (MMP-3) levels in CATH.a cells (IC50s = 1.8 and 0.06 µM, respectively). PTIQ inhibits LPS-induced production of MMP-3, TNF-α, and COX-2 in BV-2 microglia (IC50s = 2.4, 6.5, and 9.3 µM, respectively). In vivo, PTIQ (3 and 30 mg/kg) increases survival of striatal nigral dopaminergic neurons, reduces microglial activation, and alleviates motor deficits in a mouse model of MPTP-induced Parkinson’s disease.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Son, H.J., Lee, J.A., Shin, N., et alA novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson’s disease induced by MPTP. Br. J. Pharmacol. 165(7), 2213-2227 (2012).